Market News AIOpen the app

ENDRA Life Sciences shared its financial results for the third quarter of 2026 and said its merger with Noble Africa is almost done.

ResultsRead the original at SEC EDGAR
Neutral

ENDRA used more cash in operations, but its net loss narrowed, mainly because of other income. A proposed $50 million placement still depends on closing conditions, so the report does not change ENDRA's outlook.

NDRA · ENDRA Life Sciences Inc.

AI read · Neutral

The AI's read

The smaller loss did not come from stronger day-to-day business: cash use and operating costs rose, and research spending fell. Much of the loss improvement came from other income. The proposed $50 million placement depends on closing steps, and ENDRA has not received that money.

ASPI · ASP Isotopes Inc.

AI read · Neutral

The connection

ASP Isotopes plans to contribute its ownership interest in Renergen to Noble Africa as part of the proposed merger, which may also bring in about $50 million. The deal is not complete, and the filing does not explain a clear effect on ASP Isotopes' business.

Get alerts for NDRA

Follow ENDRA Life Sciences Inc. (NDRA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for NDRA
Free on the App Store and Google Play, or on the web.